Merck & Co., Inc. (MRK)
NYSE · Rahway, New Jersey, USA · Founded 1891 · CEO Robert Davis
Valuation summary
$53.38 fair value versus $132.81 in the market, a difference of -59.8%. Rated Sell.
| Fair value per share | $53.38 |
| Current share price | $132.81 |
| Upside / downside | -59.8% |
| Bear case | $28.42 |
| Bull case | $89.89 |
| Discount rate (WACC) | 8.6% |
| Terminal growth | 2.20% |
| Market capitalisation | $328B |
| EV / Sales | 5.5x |
About Merck & Co., Inc.
Founded in 1891 as the US subsidiary of the German chemical firm Merck, becoming independent after the First World War. Headquartered in Rahway, New Jersey; Robert Davis is CEO. The company is defined by Keytruda, the PD-1 checkpoint inhibitor that is the best-selling drug in the world and treats a growing list of cancers. Other products include Gardasil for HPV, the Januvia diabetes franchise, and a large animal health division. Merck's central challenge is the Keytruda patent cliff arriving in 2028.
Investment case
- Keytruda continues to add indications, and the subcutaneous Keytruda Qlex, which contributed $463M of second-quarter 2026 sales, can extend the franchise's effective life.
- Animal health is a genuinely good, non-correlated business that the market largely ignores.
- The valuation already discounts a sharp Keytruda cliff, which is why our model deliberately builds a decline year into the forecast.
Key risks
- Keytruda is roughly half of revenue and loses exclusivity in 2028. This is one of the largest patent cliffs in industry history.
- Gardasil demand in China collapsed and has not recovered.
- The positive Phase 3 melanoma result for intismeran in August 2026 helps, but no pipeline asset has yet shown it can replace revenue on Keytruda's scale.
Recent developments
- 2026-10-29 · Q3 sales up 5% to $18.1bn; Keytruda IV sales slip 5% to $7.8bn as patients move to subcutaneous Keytruda Qlex at $830m source
- 2026-08-19 · Phase 3 INTerpath-001: intismeran autogene plus Keytruda met recurrence-free and distant-metastasis-free survival endpoints in resected melanoma; shares jumped about 12%. source
- 2026-08-04 · Q2 sales $16.6B, up 5%; Keytruda $8.4B incl. $463M Keytruda Qlex; 2026 sales guide raised to $66.3-67.3B, non-GAAP EPS cut to $2.66-2.76 on Terns charge. source
Revenue by segment
| Oncology (Keytruda-led) | 50% |
| Vaccines | 17% |
| Animal Health | 12% |
| Other pharma | 21% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $70.4B | $8.8B |
| Year 2 | $73.8B | $9.5B |
| Year 3 | $77.4B | $10.2B |
| Year 4 | $81.2B | $10.9B |
| Year 5 | $85.2B | $11.7B |
What the street says
The Keytruda cliff still dominates every conversation. Shares rose about 12% on the August 2026 intismeran melanoma data, which strengthened the bull argument that the pipeline and business development can fill the gap; bears say no pipeline can replace $30B of revenue.
Comparable companies: AZN · UNH · TMO · SYK · JNJ · NVS · MDT · BSX
Open the interactive model, price chart and sensitivity grid →